Seroatlas · Human Serome Atlas

DYNLT2

Dynein light chain Tctex-type protein 2

Also known as: DYLT2_HUMAN, TCTE3, TCTEX1D3, TCTEX2, Tctex4

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IZS6
Gene: DYNLT2
Ensembl: ENSG00000184786
Chromosome: 6
Canonical length: 198 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable dynein intermediate chain binding activity. Predicted to be involved in microtubule-based movement. Predicted to be located in cytosol and sperm flagellum. Predicted to be part of cytoplasmic dynein complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

198 residues, UniProt reviewed canonical sequence.

>Q8IZS6|DYNLT2
     1  MEKRGRGVKS SPIQTPNQTP QQAPVTPRKE RRPSMFEKEA YTQILRERLR ESIHNVQYVE
    61  PPFDDSIADI GKEWKSALAK LKFANSYRME PLKKFQAHSV ETKVQQILTE SLKDVKYDDK
   121  VFSHLSLELA DRILLAVKEF GYHRYKFIIK VLFIQKTGQA INIASRWIWD IAWDSWVAAK
   181  HEAESYVALV LVFALYYE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DYNLT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.44
Highest tissue expression: 17 nTPM

Expression across tissuesHPA

Tissue

testis: 17 nTPM
bone marrow: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM

Single-cell type

late primary spermatocytes: 317 nCPM
early spermatids: 145 nCPM
late spermatids: 26 nCPM
oligodendrocytes: 11 nCPM
microglia: 11 nCPM
bergmann glia: 9.9 nCPM

Immune cell

memory CD4 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

hypothalamus: 1.5 nTPM
pons: 0.8 nTPM
medulla oblongata: 0.7 nTPM
midbrain: 0.7 nTPM
white matter: 0.7 nTPM
basal ganglia: 0.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.83
gnomAD pLI: 0
DepMap mean gene effect: 0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

microtubule-based movement

Molecular functions

dynein intermediate chain binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of DYNLT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DYNLT2 as an antibody target. Whether an autoantibody or antibody against DYNLT2 could matter depends on whether native DYNLT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DYNLT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DYNLT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...